Efficacy and Safety of Lenvatinib for Unresectable Anaplastic Thyroid Cancer

• Published in: Gan to kagaku ryoho Vol. 44; no. 8; p. 695
• Main Authors: Yamazaki, Haruhiko, Shimizu, Satoru, Iwasaki, Hiroyuki, Yoshida, Tatsuya, Suganuma, Nobuyasu, Yamanaka, Takashi, Kojima, Izumi, Masudo, Katsuhiko, Toda, Soji, Nakayama, Hirotaka, Masuda, Munetaka
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.08.2017
• Subjects: Aged; Aged, 80 and over; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Female; Humans; Male; Phenylurea Compounds - adverse effects; Phenylurea Compounds - therapeutic use; Quinolines - adverse effects; Quinolines - therapeutic use; Thyroid Carcinoma, Anaplastic - drug therapy; Thyroid Neoplasms - drug therapy; Thyroid Neoplasms - pathology; Treatment Outcome
• ISSN: 0385-0684

The 208 trial showed that lenvatinib has a significant antitumor effect on unresectable anaplastic thyroid cancer(ATC). Herein, we present a retrospective review of data from 7 patients with unresectable ATC who received lenvatinib in our hospital between May 2015 and October 2016. Two patients were men and 5 were women. The median age was 78(range, 72-85)years, and 1 patient had Stage IV A disease, 1 had Stage IV B, and 5 had Stage IV C at diagnosis, respectively. Three patients experienced a partial response and 1 patient experienced stable disease. The response rate was 43%, and the disease control rate was 57%. The median progression-free survival(PFS)was 4.1(range, 1.1-12.2)months. Grade 3 and Grade 4 gastrointestinal hemorrhage were observed in 2patients and Grade 3 anorexia was observed in 1 patient. Further clinical research seems to be needed to establish a treatment strategy involving lenvatinib for ATC.